Haisco Pharmaceutical Group
Market Cap
CN¥29.5b
Last Updated
2021/04/11 09:09 UTC
Data Sources
Company Financials +
Executive Summary
Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. More Details
Rewards
Risk Analysis
Snowflake Analysis
Solid track record with reasonable growth potential.
Share Price & News
How has Haisco Pharmaceutical Group's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 002653 is more volatile than 75% of CN stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: 002653's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of CN stocks.
Market Performance
7 Day Return
6.4%
2653
-0.1%
CN Pharmaceuticals
-1.1%
CN Market
1 Year Return
31.6%
2653
15.8%
CN Pharmaceuticals
28.4%
CN Market
Return vs Industry: 002653 exceeded the CN Pharmaceuticals industry which returned 15.8% over the past year.
Return vs Market: 002653 exceeded the CN Market which returned 28.4% over the past year.
Shareholder returns
| 2653 | Industry | Market | |
|---|---|---|---|
| 7 Day | 6.4% | -0.1% | -1.1% |
| 30 Day | 13.5% | 3.9% | 1.0% |
| 90 Day | 59.6% | -5.4% | -5.8% |
| 1 Year | 32.0%31.6% | 16.9%15.8% | 30.4%28.4% |
| 3 Year | 133.7%123.9% | 25.2%20.7% | 25.9%19.9% |
| 5 Year | 76.0%60.3% | 41.6%34.1% | 23.6%15.5% |
Long-Term Price Volatility Vs. Market
How volatile is Haisco Pharmaceutical Group's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Haisco Pharmaceutical Group undervalued compared to its fair value and its price relative to the market?
47.05x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 002653 (CN¥27.76) is trading above our estimate of fair value (CN¥4.74)
Significantly Below Fair Value: 002653 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 002653 is poor value based on its PE Ratio (47.1x) compared to the CN Pharmaceuticals industry average (31.2x).
PE vs Market: 002653 is poor value based on its PE Ratio (47.1x) compared to the CN market (33.9x).
Price to Earnings Growth Ratio
PEG Ratio: 002653 is poor value based on its PEG Ratio (2.1x)
Price to Book Ratio
PB vs Industry: 002653 is overvalued based on its PB Ratio (10.9x) compared to the CN Pharmaceuticals industry average (2.7x).
Future Growth
How is Haisco Pharmaceutical Group forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
22.5%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 002653's forecast earnings growth (22.5% per year) is above the savings rate (3.3%).
Earnings vs Market: 002653's earnings (22.5% per year) are forecast to grow slower than the CN market (23.4% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 002653's revenue (18.7% per year) is forecast to grow faster than the CN market (17.9% per year).
High Growth Revenue: 002653's revenue (18.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 002653's Return on Equity is forecast to be high in 3 years time (21%)
Past Performance
How has Haisco Pharmaceutical Group performed over the past 5 years?
9.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 002653 has a high level of non-cash earnings.
Growing Profit Margin: 002653's current net profit margins (19.1%) are higher than last year (12.6%).
Past Earnings Growth Analysis
Earnings Trend: 002653's earnings have grown by 9.3% per year over the past 5 years.
Accelerating Growth: 002653's earnings growth over the past year (28.7%) exceeds its 5-year average (9.3% per year).
Earnings vs Industry: 002653 earnings growth over the past year (28.7%) exceeded the Pharmaceuticals industry 10.8%.
Return on Equity
High ROE: 002653's Return on Equity (21.1%) is considered high.
Financial Health
How is Haisco Pharmaceutical Group's financial position?
Financial Position Analysis
Short Term Liabilities: 002653's short term assets (CN¥2.1B) exceed its short term liabilities (CN¥1.7B).
Long Term Liabilities: 002653's short term assets (CN¥2.1B) exceed its long term liabilities (CN¥425.6M).
Debt to Equity History and Analysis
Debt Level: 002653's debt to equity ratio (38.7%) is considered satisfactory.
Reducing Debt: 002653's debt to equity ratio has increased from 29.2% to 38.7% over the past 5 years.
Debt Coverage: 002653's debt is not well covered by operating cash flow (18.7%).
Interest Coverage: 002653 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Haisco Pharmaceutical Group current dividend yield, its reliability and sustainability?
1.34%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 002653's dividend (1.34%) is higher than the bottom 25% of dividend payers in the CN market (0.43%).
High Dividend: 002653's dividend (1.34%) is low compared to the top 25% of dividend payers in the CN market (1.81%).
Stability and Growth of Payments
Stable Dividend: 002653 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 002653's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (63.1%), 002653's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
0.9yrs
Average board tenure
CEO
Jun Min Wang (50 yo)
no data
Tenure
CN¥319,300
Compensation
Mr. Wang Jun Min is the Founder of Haisco Pharmaceutical and also serves as its President and Chief Executive Officer. Mr. Wang serves as the Chairman and General Manager of Haisco Pharmaceutical Group Co....
Board Members
Experienced Board: 002653's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Haisco Pharmaceutical Group Co., Ltd.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Haisco Pharmaceutical Group Co., Ltd.
- Ticker: 2653
- Exchange: SZSE
- Founded: 2000
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CN¥29.532b
- Shares outstanding: 1.06b
- Website: https://www.haisco.com
Number of Employees
Location
- Haisco Pharmaceutical Group Co., Ltd.
- Taiwan Strait Technology Industry Development Park
- No. 136, Baili Road
- Chengdu
- Sichuan Province
- China
Listings
Biography
Haisco Pharmaceutical Group Co., Ltd., together with its subsidiaries, develops, produces, and sells drugs in China. The company offers capsules, tablets, granules, and bulk drugs in the fields of cardiova...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/04/11 09:09 |
| End of Day Share Price | 2021/04/09 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.